MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598771 | Name: Sorbinicate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sorbinicate is an antihypercholesterolaemic and/or vasodilating nicotinic acid ester.

Chemical Structure

Sorbinicate
Sorbinicate
CAS#6184-06-1

Theoretical Analysis

MedKoo Cat#: 598771

Name: Sorbinicate

CAS#: 6184-06-1

Chemical Formula: C42H32N6O12

Exact Mass: 812.2078

Molecular Weight: 812.74

Elemental Analysis: C, 62.07; H, 3.97; N, 10.34; O, 23.62

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sorbinicate; Sorbinicatum; LG 10017; LG-10017; LG10017; LG10,017; LG-10,017; LG 10,017;
IUPAC/Chemical Name
(2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexayl hexanicotinate
InChi Key
IMRLNFKFNFLWQF-IYKITFJXSA-N
InChi Code
InChI=1S/C42H32N6O12/c49-37(27-7-1-13-43-19-27)55-25-33(57-39(51)29-9-3-15-45-21-29)35(59-41(53)31-11-5-17-47-23-31)36(60-42(54)32-12-6-18-48-24-32)34(58-40(52)30-10-4-16-46-22-30)26-56-38(50)28-8-2-14-44-20-28/h1-24,33-36H,25-26H2/t33-,34+,35-,36-/m1/s1
SMILES Code
O=C(OC[C@H](OC(C1=CN=CC=C1)=O)[C@@H](OC(C2=CN=CC=C2)=O)[C@H](OC(C3=CN=CC=C3)=O)[C@H](OC(C4=CN=CC=C4)=O)COC(C5=CN=CC=C5)=O)C6=CN=CC=C6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 812.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Giachetti C, Mondino A, Silvestri S, Zanolo G, Bramanti G, Criscuoli M, Subissi A. On the absorption, distribution and excretion of sorbinicate in the rat and the monkey. Arzneimittelforschung. 1982;32(11):1433-6. PubMed PMID: 6891249. 2: Strano A, Novo S, Davì G, Avellone G, Mandalà V. Effects of sorbinicate and nicotinic acid on blood viscosity, red cell deformation and platelet function. Pharmacol Res Commun. 1982 Jul;14(7):639-48. PubMed PMID: 7134249. 3: Subissi A, Murmann W. Correlation between the plasma concentration of free nicotinic acid and some of its pharmacological effects in the fasted rat after an oral dose of sorbinicate and of nicotinic acid. Arzneimittelforschung. 1978;28(7):1143-5. PubMed PMID: 582703. 4: Subissi A, Biagi M, Murmann W. Some aspects of sorbinicate pharmacokinetics. Arzneimittelforschung. 1980;30(8):1278-84. PubMed PMID: 7192142. 5: Lanza E, Dionigi R, Subissi A, Piccinini F. Effects of experimental atherosclerosis on cerebral blood flow in rabbits. Reversal by sorbinicate. Artery. 1982;11(1):64-73. PubMed PMID: 7171322. 6: Guida L, Grimaldi S, Avella F, Marullo L, Mascio G. [The use of sorbinicate in the treatment of hyperlipoproteinemia type IIa and IIb]. Farmaco Prat. 1981 Jan;36(1):13-22. Italian. PubMed PMID: 7227491. 7: Uccella R, Morenghi R, Agosti C, Saponati G. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate). Artery. 1983;11(5):400-12. PubMed PMID: 6661043. 8: Subissi A, Schiantarelli P, Biagi M, Sardelli G. Comparative evaluation of some pharmacological properties and side effects of D-glucitol hexanicotinate (sorbinicate) and nicotinic acid correlated with the plasma concentration of nicotinic acid. Atherosclerosis. 1980 May;36(1):135-48. PubMed PMID: 7387773. 9: Bonfiglioli D, Sommariva D, Rovelli L, Panigo F, Gatti P, Cialfi A, Grimoldi M, Cabrini E, Fasoli A. [Effect of sorbinicate on blood proteins and platelet aggregation in patients with coronary disease]. Clin Ter. 1984 Jul 31;110(2):111-8. Italian. PubMed PMID: 6237851. 10: Avogaro P, Bittolo-Bon G, Cazzolato G. Effect of sorbinicate (nicotinic hexaester of D-glucitol) on the plasma FFA; plasma levels of nicotinic acid after sorbinicate administration. Pharmacol Res Commun. 1978 Feb;10(2):127-31. PubMed PMID: 349572. 11: Sommariva D, Panigo FE, Rovelli L, Bonfiglioli D, Garimoldi M, Cialfi A, Gandini R, Fasoli A. Effect of D-glucitol-hexanicotinate on platelet aggregability in patients with coronary heart disease. Int J Clin Pharmacol Ther Toxicol. 1984 May;22(5):265-8. PubMed PMID: 6746150. 12: Zuliani U, Bonetti A, Orlandini G, Manari A, David S, Garini G. [Pharmacokinetics and antilipolytic effect of a derivative of nicotinic acid (sorbinicate) in dialyzed uremic patients]. Farmaco Prat. 1981 Sep;36(9):416-23. Italian. PubMed PMID: 7308427. 13: Subissi A, Criscuoli M, Biagi M, Murmann W. Acute effects on plasma lipids in the rat of a new long-acting nicotinic acid derivative: LG 13979. J Pharm Pharmacol. 1983 Sep;35(9):571-5. PubMed PMID: 6138406. 14: Santagostino A, Pagani G, Ballerio G, Porro T. Metabolic changes induced by a nicotinic acid derivative in patients with obesity grades 1, 2 and 3. Panminerva Med. 1979 Jul-Sep;21(3):111-26. PubMed PMID: 554045. 15: Mäkinen KK, Saag M, Isotupa KP, Olak J, Nõmmela R, Söderling E, Mäkinen PL. Similarity of the effects of erythritol and xylitol on some risk factors of dental caries. Caries Res. 2005 May-Jun;39(3):207-15. PubMed PMID: 15914983. 16: Subissi A, Bachi M, Brunori P. Some cardiovascular effects of LG 13979: comparison with nicotinic acid and other nicotinic acid derivatives. J Pharm Pharmacol. 1983 Sep;35(9):612-4. PubMed PMID: 6138419. 17: Novo S, Avellone G, Pinto A, Fazio M. [Activation of fibrinolysis induced by D-glucitol-hexanicotinate]. Farmaco Prat. 1980 Mar;35(3):155-60. Italian. PubMed PMID: 7439356. 18: Avellone G, Novo S, Mandalà V. [D-glucitol hexanicotinate and platelet aggregation]. Farmaco Prat. 1980 Mar;35(3):147-54. Italian. PubMed PMID: 7439355.